25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Adverum Biotechnologies Inc
Buy, Hold or Sell?

Let's analyze Adverum together

I guess you are interested in Adverum Biotechnologies Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adverum Biotechnologies Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adverum Biotechnologies Inc

I send you an email if I find something interesting about Adverum Biotechnologies Inc.

1. Quick Overview

1.1. Quick analysis of Adverum (30 sec.)










1.2. What can you expect buying and holding a share of Adverum? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.90
Expected worth in 1 year
$8.87
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$1.97
Return On Investment
45.8%

For what price can you sell your share?

Current Price per Share
$4.29
Expected price per share
$0 - $5.63
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adverum (5 min.)




Live pricePrice per Share (EOD)
$4.29
Intrinsic Value Per Share
$-57.08 - $-28.28
Total Value Per Share
$-50.17 - $-21.38

2.2. Growth of Adverum (5 min.)




Is Adverum growing?

Current yearPrevious yearGrowGrow %
How rich?$144.1m$143.2m$1.1m0.8%

How much money is Adverum making?

Current yearPrevious yearGrowGrow %
Making money-$23.5m-$31.5m$8m34.1%
Net Profit Margin-513.7%-201.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Adverum (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#302 / 933

Most Revenue
#925 / 933

Most Profit
#671 / 933

Most Efficient
#623 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adverum?

Welcome investor! Adverum's management wants to use your money to grow the business. In return you get a share of Adverum.

First you should know what it really means to hold a share of Adverum. And how you can make/lose money.

Speculation

The Price per Share of Adverum is $4.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adverum.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adverum, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.90. Based on the TTM, the Book Value Change Per Share is $0.49 per quarter. Based on the YOY, the Book Value Change Per Share is $0.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adverum.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.30-30.3%-1.13-26.3%-1.52-35.3%-0.75-17.4%-0.61-14.2%
Usd Book Value Change Per Share-1.15-26.9%0.4911.5%0.7116.6%0.225.1%-0.01-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.15-26.9%0.4911.5%0.7116.6%0.225.1%-0.01-0.3%
Usd Price Per Share7.02-7.19-1.10-5.86-7.91-
Price to Earnings Ratio-1.35--1.60--0.18--3.55--4.63-
Price-to-Total Gains Ratio-6.08--3.41--0.72--9.96--12.80-
Price to Book Ratio1.02-0.92-0.18-1.39-1.55-
Price-to-Total Gains Ratio-6.08--3.41--0.72--9.96--12.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.29
Number of shares233
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.490.22
Usd Total Gains Per Share0.490.22
Gains per Quarter (233 shares)114.5150.76
Gains per Year (233 shares)458.04203.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104584480203193
209169060406396
30137413640609599
40183218220812802
5022902280010151005
6027482738012181208
7032063196014211411
8036643654016241614
9041224112018271817
10045804570020302020

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.047.01.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%6.034.00.015.0%9.036.03.018.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%6.034.00.015.0%9.036.03.018.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adverum Biotechnologies Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.1550.491-335%0.711-262%0.218-630%-0.015-99%
Book Value Per Share--6.9036.9340%6.888+0%4.863+42%5.302+30%
Current Ratio--5.8246.795-14%4.292+36%11.476-49%18.726-69%
Debt To Asset Ratio--0.3850.390-1%0.443-13%0.300+29%0.189+104%
Debt To Equity Ratio--0.6260.670-6%0.801-22%0.478+31%0.283+121%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--209531520.000216302428.000-3%62665871.813+234%552102306.963-62%550441369.017-62%
Eps---1.300-1.129-13%-1.516+17%-0.746-43%-0.609-53%
Ev To Ebitda Ratio---1.996-2.303+15%-0.501-75%-4.912+146%-9.595+381%
Ev To Sales Ratio--52.383infnan%infnan%infnan%infnan%
Free Cash Flow Per Share---1.022-1.034+1%-1.068+4%-0.603-41%-0.440-57%
Free Cash Flow To Equity Per Share---1.0220.409-350%-1.076+5%-0.077-92%0.001-128363%
Gross Profit Margin--1.0001.112-10%1.0000%1.022-2%1.011-1%
Intrinsic Value_10Y_max---28.283--------
Intrinsic Value_10Y_min---57.077--------
Intrinsic Value_1Y_max---1.918--------
Intrinsic Value_1Y_min---3.689--------
Intrinsic Value_3Y_max---6.461--------
Intrinsic Value_3Y_min---12.909--------
Intrinsic Value_5Y_max---11.846--------
Intrinsic Value_5Y_min---24.057--------
Market Cap89242725.000-64%146549520.000149850428.000-2%22814621.813+542%397344756.963-63%371499369.017-61%
Net Profit Margin---27.134-5.137-81%-2.018-93%2.394-1233%-30.708+13%
Operating Margin---27.134-4.899-82%-2.199-92%2.296-1282%-22.327-18%
Operating Ratio--31.1115.975+421%2.560+1115%-2.312+107%50.179-38%
Pb Ratio0.621-64%1.0170.917+11%0.179+467%1.387-27%1.549-34%
Pe Ratio-0.825+39%-1.350-1.604+19%-0.180-87%-3.551+163%-4.630+243%
Price Per Share4.290-64%7.0207.193-2%1.097+540%5.861+20%7.908-11%
Price To Free Cash Flow Ratio-1.049+39%-1.716-1.7120%-0.251-85%-4.253+148%-6.689+290%
Price To Total Gains Ratio-3.715+39%-6.079-3.413-44%-0.720-88%-9.964+64%-12.798+111%
Quick Ratio--7.9828.460-6%5.846+37%19.096-58%26.096-69%
Return On Assets---0.116-0.105-10%-0.127+10%-0.097-17%-0.085-26%
Return On Equity---0.188-0.180-5%-0.231+23%-0.149-21%-0.115-39%
Total Gains Per Share---1.1550.491-335%0.711-262%0.218-630%-0.015-99%
Usd Book Value--144116000.000144475499.7500%143286000.000+1%250156799.950-42%233594624.975-38%
Usd Book Value Change Per Share---1.1550.491-335%0.711-262%0.218-630%-0.015-99%
Usd Book Value Per Share--6.9036.9340%6.888+0%4.863+42%5.302+30%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--209531520.000216302428.000-3%62665871.813+234%552102306.963-62%550441369.017-62%
Usd Eps---1.300-1.129-13%-1.516+17%-0.746-43%-0.609-53%
Usd Free Cash Flow---21345000.000-21534000.000+1%-22212500.000+4%-25676500.000+20%-18611900.000-13%
Usd Free Cash Flow Per Share---1.022-1.034+1%-1.068+4%-0.603-41%-0.440-57%
Usd Free Cash Flow To Equity Per Share---1.0220.409-350%-1.076+5%-0.077-92%0.001-128363%
Usd Market Cap89242725.000-64%146549520.000149850428.000-2%22814621.813+542%397344756.963-63%371499369.017-61%
Usd Price Per Share4.290-64%7.0207.193-2%1.097+540%5.861+20%7.908-11%
Usd Profit---27134000.000-23527750.000-13%-31546750.000+16%-31203500.000+15%-24249900.000-11%
Usd Revenue--1000000.000-650000.000+165%900000.000+11%37500.000+2567%212700.000+370%
Usd Total Gains Per Share---1.1550.491-335%0.711-262%0.218-630%-0.015-99%
 EOD+3 -5MRQTTM+9 -28YOY+25 -115Y+9 -2810Y+9 -28

3.3 Fundamental Score

Let's check the fundamental score of Adverum Biotechnologies Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.825
Price to Book Ratio (EOD)Between0-10.621
Net Profit Margin (MRQ)Greater than0-27.134
Operating Margin (MRQ)Greater than0-27.134
Quick Ratio (MRQ)Greater than17.982
Current Ratio (MRQ)Greater than15.824
Debt to Asset Ratio (MRQ)Less than10.385
Debt to Equity Ratio (MRQ)Less than10.626
Return on Equity (MRQ)Greater than0.15-0.188
Return on Assets (MRQ)Greater than0.05-0.116
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Adverum Biotechnologies Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.461
Ma 20Greater thanMa 504.686
Ma 50Greater thanMa 1005.829
Ma 100Greater thanMa 2006.591
OpenGreater thanClose4.700
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2025-01-16 11:49:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Adverum earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Net Profit Margin of -2,713.4% means that $-27.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is -2,713.4%. The company is making a huge loss. -2
  • The TTM is -513.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,713.4%TTM-513.7%-2,199.7%
TTM-513.7%YOY-201.8%-311.9%
TTM-513.7%5Y239.4%-753.1%
5Y239.4%10Y-3,070.8%+3,310.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,713.4%-104.6%-2,608.8%
TTM-513.7%-216.4%-297.3%
YOY-201.8%-208.6%+6.8%
5Y239.4%-353.9%+593.3%
10Y-3,070.8%-488.0%-2,582.8%
4.3.1.2. Return on Assets

Shows how efficient Adverum is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • -11.6% Return on Assets means that Adverum generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adverum Biotechnologies Inc:

  • The MRQ is -11.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-10.5%-1.1%
TTM-10.5%YOY-12.7%+2.3%
TTM-10.5%5Y-9.7%-0.8%
5Y-9.7%10Y-8.5%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-12.7%+1.1%
TTM-10.5%-13.0%+2.5%
YOY-12.7%-12.3%-0.4%
5Y-9.7%-13.7%+4.0%
10Y-8.5%-15.7%+7.2%
4.3.1.3. Return on Equity

Shows how efficient Adverum is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • -18.8% Return on Equity means Adverum generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adverum Biotechnologies Inc:

  • The MRQ is -18.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.8%TTM-18.0%-0.9%
TTM-18.0%YOY-23.1%+5.2%
TTM-18.0%5Y-14.9%-3.0%
5Y-14.9%10Y-11.5%-3.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.8%-16.8%-2.0%
TTM-18.0%-17.8%-0.2%
YOY-23.1%-16.4%-6.7%
5Y-14.9%-20.6%+5.7%
10Y-11.5%-21.2%+9.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adverum Biotechnologies Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Adverum is operating .

  • Measures how much profit Adverum makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • An Operating Margin of -2,713.4% means the company generated $-27.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is -2,713.4%. The company is operating very inefficient. -2
  • The TTM is -489.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,713.4%TTM-489.9%-2,223.5%
TTM-489.9%YOY-219.9%-270.0%
TTM-489.9%5Y229.6%-719.5%
5Y229.6%10Y-2,232.7%+2,462.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,713.4%-193.6%-2,519.8%
TTM-489.9%-321.1%-168.8%
YOY-219.9%-227.9%+8.0%
5Y229.6%-373.0%+602.6%
10Y-2,232.7%-506.1%-1,726.6%
4.3.2.2. Operating Ratio

Measures how efficient Adverum is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 31.11 means that the operating costs are $31.11 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 31.111. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.975. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ31.111TTM5.975+25.136
TTM5.975YOY2.560+3.416
TTM5.9755Y-2.312+8.287
5Y-2.31210Y50.179-52.491
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.1112.171+28.940
TTM5.9753.250+2.725
YOY2.5603.231-0.671
5Y-2.3124.838-7.150
10Y50.1796.440+43.739
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adverum Biotechnologies Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adverum is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.82 means the company has $5.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 5.824. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.795. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.824TTM6.795-0.970
TTM6.795YOY4.292+2.503
TTM6.7955Y11.476-4.681
5Y11.47610Y18.726-7.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8243.610+2.214
TTM6.7953.850+2.945
YOY4.2924.605-0.313
5Y11.4765.895+5.581
10Y18.7266.178+12.548
4.4.3.2. Quick Ratio

Measures if Adverum is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Quick Ratio of 7.98 means the company can pay off $7.98 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 7.982. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.460. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.982TTM8.460-0.478
TTM8.460YOY5.846+2.614
TTM8.4605Y19.096-10.636
5Y19.09610Y26.096-7.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9823.034+4.948
TTM8.4603.355+5.105
YOY5.8464.297+1.549
5Y19.0965.890+13.206
10Y26.0966.434+19.662
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adverum Biotechnologies Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Adverum assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adverum to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.39 means that Adverum assets are financed with 38.5% credit (debt) and the remaining percentage (100% - 38.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.385. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.390. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.385TTM0.390-0.005
TTM0.390YOY0.443-0.053
TTM0.3905Y0.300+0.090
5Y0.30010Y0.189+0.110
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3850.341+0.044
TTM0.3900.343+0.047
YOY0.4430.310+0.133
5Y0.3000.366-0.066
10Y0.1890.385-0.196
4.5.4.2. Debt to Equity Ratio

Measures if Adverum is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Debt to Equity ratio of 62.6% means that company has $0.63 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.626. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.670. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.626TTM0.670-0.043
TTM0.670YOY0.801-0.131
TTM0.6705Y0.478+0.192
5Y0.47810Y0.283+0.195
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6260.393+0.233
TTM0.6700.429+0.241
YOY0.8010.382+0.419
5Y0.4780.439+0.039
10Y0.2830.489-0.206
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Adverum generates.

  • Above 15 is considered overpriced but always compare Adverum to the Biotechnology industry mean.
  • A PE ratio of -1.35 means the investor is paying $-1.35 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -0.825. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.350. Based on the earnings, the company is expensive. -2
  • The TTM is -1.604. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.825MRQ-1.350+0.525
MRQ-1.350TTM-1.604+0.254
TTM-1.604YOY-0.180-1.424
TTM-1.6045Y-3.551+1.947
5Y-3.55110Y-4.630+1.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.825-2.247+1.422
MRQ-1.350-2.693+1.343
TTM-1.604-3.214+1.610
YOY-0.180-3.335+3.155
5Y-3.551-6.368+2.817
10Y-4.630-6.692+2.062
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -1.049. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.716. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.712. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.049MRQ-1.716+0.668
MRQ-1.716TTM-1.712-0.004
TTM-1.712YOY-0.251-1.462
TTM-1.7125Y-4.253+2.540
5Y-4.25310Y-6.689+2.436
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.049-2.993+1.944
MRQ-1.716-3.671+1.955
TTM-1.712-4.037+2.325
YOY-0.251-4.482+4.231
5Y-4.253-8.190+3.937
10Y-6.689-9.383+2.694
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Adverum is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.02 means the investor is paying $1.02 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is 0.621. Based on the equity, the company is cheap. +2
  • The MRQ is 1.017. Based on the equity, the company is underpriced. +1
  • The TTM is 0.917. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.621MRQ1.017-0.395
MRQ1.017TTM0.917+0.100
TTM0.917YOY0.179+0.738
TTM0.9175Y1.387-0.470
5Y1.38710Y1.549-0.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6211.933-1.312
MRQ1.0172.265-1.248
TTM0.9172.447-1.530
YOY0.1792.454-2.275
5Y1.3873.664-2.277
10Y1.5494.239-2.690
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adverum Biotechnologies Inc.

4.8.1. Institutions holding Adverum Biotechnologies Inc

Institutions are holding 78.997% of the shares of Adverum Biotechnologies Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30BML Capital Management LLC10.90299.3686226806430206415.3644
2024-09-30TCG Crossover Management, LLC9.65431.1945200833920083390
2024-09-30Franklin Resources Inc8.46080.0038176005640.0002
2024-09-30BlackRock Inc7.1660.00021490709812685.766
2024-09-30VR Adviser, LLC7.05230.5394146704800
2024-09-30Vanguard Group Inc4.94010.00011027654181951.8025
2024-09-30Vivo Capital, LLC4.00590.484183333300
2024-09-305AM Venture Management, LLC2.60390.785654166600
2024-09-30Versant Venture Management LLC2.43645.596550682100
2024-09-30Geode Capital Management, LLC2.11060.0003439056-16731-3.6708
2024-09-30Goldman Sachs Group Inc2.03860.0005424087271566.8415
2024-09-30Logos Global Management LP2.0030.3156416666-416666-50
2024-09-30State Street Corp1.77680.00013696169111232.7148
2024-09-30Pale Fire Capital SE1.48240.33953083713083710
2024-09-30Soleus Capital Management, L.P.1.38080.156128724614000095.079
2024-09-30FMR Inc1.12830.0001234718-402791-63.182
2024-09-30Dimensional Fund Advisors, Inc.0.99380.0004206743-16684-7.4673
2024-09-30Nuveen Asset Management, LLC0.83490.0003173677105140153.4062
2024-09-30Northern Trust Corp0.74510.0002154997107834228.6411
2024-09-30Morgan Stanley - Brokerage Accounts0.42870.000189183-169335-65.5022
Total 72.145618.78615008050+2167276+14.4%

4.9.2. Funds holding Adverum Biotechnologies Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Franklin Biotechnology Discv A(acc)USD5.45730.5037113524900
2024-11-30Franklin Biotechnology Discovery A3.00320.477162473700
2024-11-30Vanguard Total Stock Mkt Idx Inv2.81820.000258624500
2024-12-31iShares Russell 2000 ETF2.73130.0037568187-2175-0.3813
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.37390.001628579600
2024-11-30CREF Stock R11.1240.00122338309200064.8664
2024-10-31Fidelity Small Cap Index1.00160.0057208353-149-0.0715
2024-12-31iShares Russell 2000 Value ETF0.92280.0073191975-5376-2.7241
2024-11-30Vanguard Russell 2000 ETF0.46680.00469711325482.6944
2024-12-31State St Russell Sm/Mid Cp® Indx NL Cl C0.45440.00194527-1600-1.6645
2024-11-30Fidelity Extended Market Index0.43470.001490421-596-0.6548
2024-11-30Fidelity Select Biotechnology0.35190.010273213-66800-47.7099
2024-06-30Galileo - Biotech Innovation Fund S USD0.33311.32116930300
2024-12-31State St Russell Sm Cap® Indx SL Cl I0.32110.00336680000
2024-09-30NT R2000 Value Index Fund - NL0.23790.010549482494820
2024-11-30Schwab Small Cap Index0.23560.00464902100
2024-09-30NT R2000 Index Fund - NL0.23510.005248910489100
2024-11-30DFA US Small Cap I0.23360.001848596450010.205
2024-12-31iShares Micro-Cap ETF0.23020.02344788500
2024-09-30NT R2000 Value Index Fund - L0.20740.011343153431530
Total 22.17412.39894612796+163897+3.6%

5.3. Insider Transactions

Insiders are holding 16.716% of the shares of Adverum Biotechnologies Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-30Braden Michael LeonardBUY858007.15
2024-07-17Braden Michael LeonardBUY1355467.75
2024-02-07James Paul ScopaBUY1000013.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Gross Profit  -1,509-3,100-4,6093,612-99741-9561,066110



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets234,375
Total Liabilities90,259
Total Stockholder Equity144,116
 As reported
Total Liabilities 90,259
Total Stockholder Equity+ 144,116
Total Assets = 234,375

Assets

Total Assets234,375
Total Current Assets161,080
Long-term Assets73,295
Total Current Assets
Cash And Cash Equivalents 92,851
Short-term Investments 60,390
Net Receivables 7,116
Total Current Assets  (as reported)161,080
Total Current Assets  (calculated)160,357
+/- 723
Long-term Assets
Property Plant Equipment 62,910
Long-term Assets Other 10,385
Long-term Assets  (as reported)73,295
Long-term Assets  (calculated)73,295
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities27,657
Long-term Liabilities62,602
Total Stockholder Equity144,116
Total Current Liabilities
Short-term Debt 10,661
Accounts payable 2,110
Other Current Liabilities 14,886
Total Current Liabilities  (as reported)27,657
Total Current Liabilities  (calculated)27,657
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt62,602
Long-term Liabilities  (as reported)62,602
Long-term Liabilities  (calculated)62,602
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -990,174
Accumulated Other Comprehensive Income -268
Other Stockholders Equity 1,134,556
Total Stockholder Equity (as reported)144,116
Total Stockholder Equity (calculated)144,116
+/-0
Other
Capital Stock2
Cash and Short Term Investments 153,241
Common Stock Shares Outstanding 20,876
Liabilities and Stockholders Equity 234,375
Net Debt -19,588
Net Invested Capital 144,116
Net Working Capital 133,423
Property Plant and Equipment Gross 80,145
Short Long Term Debt Total 73,263



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
386
0
0
0
1,085
51,613
54,789
167,239
161,906
292,691
283,715
273,829
264,319
252,934
264,345
256,571
234,583
221,929
208,579
198,210
201,905
257,158
246,585
225,907
213,495
221,047
209,884
205,525
222,727
348,599
331,176
507,711
482,567
461,551
526,147
490,581
439,727
407,394
374,955
332,362
308,372
275,577
241,429
196,770
173,010
267,828
253,803
234,375
234,375253,803267,828173,010196,770241,429275,577308,372332,362374,955407,394439,727490,581526,147461,551482,567507,711331,176348,599222,727205,525209,884221,047213,495225,907246,585257,158201,905198,210208,579221,929234,583256,571264,345252,934264,319273,829283,715292,691161,906167,23954,78951,6131,085000386
   > Total Current Assets 
0
0
0
0
822
51,266
52,904
166,333
160,278
291,132
280,632
270,361
260,992
249,229
243,570
235,896
225,274
212,640
199,641
189,523
193,741
249,198
237,922
222,174
208,754
193,137
180,561
167,602
175,870
300,448
282,681
459,700
434,438
409,855
386,272
347,827
317,145
280,117
246,031
213,243
190,595
168,873
147,143
124,596
102,773
199,130
179,418
161,080
161,080179,418199,130102,773124,596147,143168,873190,595213,243246,031280,117317,145347,827386,272409,855434,438459,700282,681300,448175,870167,602180,561193,137208,754222,174237,922249,198193,741189,523199,641212,640225,274235,896243,570249,229260,992270,361280,632291,132160,278166,33352,90451,2668220000
       Cash And Cash Equivalents 
357
0
0
0
564
50,679
52,428
165,329
159,404
290,125
200,537
200,676
259,080
247,082
241,302
231,271
222,170
71,569
39,523
31,713
70,519
152,716
155,451
159,673
154,949
144,107
97,808
73,171
65,897
130,162
27,359
72,696
62,424
45,422
47,299
32,971
34,195
89,652
91,870
84,430
68,431
67,552
111,187
105,366
75,000
149,608
127,321
92,851
92,851127,321149,60875,000105,366111,18767,55268,43184,43091,87089,65234,19532,97147,29945,42262,42472,69627,359130,16265,89773,17197,808144,107154,949159,673155,451152,71670,51931,71339,52371,569222,170231,271241,302247,082259,080200,676200,537290,125159,404165,32952,42850,679564000357
       Short-term Investments 
0
0
0
0
0
0
0
0
0
88,276
79,103
68,210
37,732
37,732
0
0
0
137,934
157,895
154,929
119,966
94,321
79,425
58,209
50,130
45,381
79,834
88,814
100,138
166,904
252,780
381,766
367,305
358,596
316,544
299,734
270,993
181,403
143,971
118,834
117,158
96,733
30,266
11,716
21,526
43,720
46,506
60,390
60,39046,50643,72021,52611,71630,26696,733117,158118,834143,971181,403270,993299,734316,544358,596367,305381,766252,780166,904100,13888,81479,83445,38150,13058,20979,42594,321119,966154,929157,895137,93400037,73237,73268,21079,10388,276000000000
       Net Receivables 
0
0
0
0
8
233
8
8
449
0
0
0
449
1,117
1,029
1,785
886
886
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,196
7,358
5,709
2,457
4,145
155
0
1,351
1,308
0
0
0
6,963
7,116
7,1166,9630001,3081,35101554,1452,4575,7097,35816,19600000000000000008868861,7851,0291,1174490004498823380000
   > Long-term Assets 
0
0
0
0
263
347
1,885
906
1,628
1,559
3,083
3,468
3,327
3,705
20,775
20,675
9,309
9,289
8,938
8,687
8,164
7,960
8,663
3,733
4,741
27,910
29,323
37,923
46,857
48,151
48,495
48,011
48,129
51,696
139,875
142,754
122,582
127,277
128,924
119,119
117,777
106,704
94,286
72,174
70,237
68,698
74,385
73,295
73,29574,38568,69870,23772,17494,286106,704117,777119,119128,924127,277122,582142,754139,87551,69648,12948,01148,49548,15146,85737,92329,32327,9104,7413,7338,6637,9608,1648,6878,9389,2899,30920,67520,7753,7053,3273,4683,0831,5591,6289061,8853472630000
       Property Plant Equipment 
4
0
0
0
69
107
509
817
1,085
1,421
2,945
3,330
3,187
3,565
3,985
4,335
4,169
4,149
3,798
3,347
3,024
2,820
2,525
2,594
3,586
26,737
28,150
36,760
45,847
47,133
47,477
46,993
47,101
47,423
133,465
137,332
119,060
122,097
121,999
116,461
113,861
102,850
90,328
68,254
67,030
65,526
64,284
62,910
62,91064,28465,52667,03068,25490,328102,850113,861116,461121,999122,097119,060137,332133,46547,42347,10146,99347,47747,13345,84736,76028,15026,7373,5862,5942,5252,8203,0243,3473,7984,1494,1694,3353,9853,5653,1873,3302,9451,4211,085817509107690004
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,650
16,200
5,000
5,000
5,000
5,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000005,0005,0005,0005,0005,0005,0005,00016,20016,65000000000000000
       Other Assets 
0
0
0
0
194
240
1,376
89
543
138
138
138
140
140
16,790
16,340
5,140
5,140
5,140
5,340
5,140
140
1,138
1,139
1,155
1,173
1,173
1,163
1,010
1,018
1,018
1,018
1,028
4,273
6,410
5,422
3,522
5,180
6,925
2,658
3,916
0
3,958
3,920
0
0
0
0
00003,9203,95803,9162,6586,9255,1803,5225,4226,4104,2731,0281,0181,0181,0181,0101,1631,1731,1731,1551,1391,1381405,1405,3405,1405,1405,14016,34016,790140140138138138543891,3762401940000
> Total Liabilities 
1,383
0
0
0
1,303
1,699
11,751
11,504
12,423
13,011
13,089
11,499
11,727
11,368
16,691
20,341
18,983
20,548
16,399
17,218
17,877
11,115
13,138
10,354
12,328
32,904
32,144
41,311
47,770
44,646
48,613
42,999
48,220
46,731
147,005
144,581
123,542
124,442
130,833
124,025
126,854
117,820
110,274
94,056
89,541
85,540
85,774
90,259
90,25985,77485,54089,54194,056110,274117,820126,854124,025130,833124,442123,542144,581147,00546,73148,22042,99948,61344,64647,77041,31132,14432,90412,32810,35413,13811,11517,87717,21816,39920,54818,98320,34116,69111,36811,72711,49913,08913,01112,42311,50411,7511,6991,3030001,383
   > Total Current Liabilities 
839
0
0
0
1,162
1,608
3,991
4,461
5,471
7,628
7,864
6,496
6,574
5,556
7,897
10,649
9,896
11,966
8,313
9,613
10,674
9,274
11,374
10,065
10,719
10,610
10,149
17,746
19,408
16,767
21,254
16,111
20,871
19,923
20,530
25,326
21,320
23,237
30,620
28,621
32,246
46,472
44,518
28,856
24,914
21,549
22,461
27,657
27,65722,46121,54924,91428,85644,51846,47232,24628,62130,62023,23721,32025,32620,53019,92320,87116,11121,25416,76719,40817,74610,14910,61010,71910,06511,3749,27410,6749,6138,31311,9669,89610,6497,8975,5566,5746,4967,8647,6285,4714,4613,9911,6081,162000839
       Short-term Debt 
0
0
0
0
0
0
1,597
1,995
3,687
2,485
3,331
3,691
4,073
3,404
4,141
5,816
6,547
6,609
5,076
5,948
6,848
6,766
7,356
7,666
0
3,826
3,942
4,044
4,034
4,025
4,221
4,435
4,473
4,512
4,185
4,224
1,886
2,359
6,292
11,236
13,241
26,265
25,396
10,324
20,818
10,492
21,152
10,661
10,66121,15210,49220,81810,32425,39626,26513,24111,2366,2922,3591,8864,2244,1854,5124,4734,4354,2214,0254,0344,0443,9423,82607,6667,3566,7666,8485,9485,0766,6096,5475,8164,1413,4044,0733,6913,3312,4853,6871,9951,597000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
74
74
157
0
0
0
0
3,826
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000100003,8260000157747474740000000000000000
       Accounts payable 
522
0
0
0
769
946
1,576
1,627
951
2,787
1,896
1,141
605
486
2,419
3,067
1,474
3,383
1,125
1,580
1,731
685
2,125
1,736
1,707
1,752
740
3,382
4,103
4,663
10,367
3,034
2,810
2,056
2,259
2,517
1,387
3,245
4,698
846
2,238
2,863
1,418
2,170
1,921
1,897
1,973
2,110
2,1101,9731,8971,9212,1701,4182,8632,2388464,6983,2451,3872,5172,2592,0562,8103,03410,3674,6634,1033,3827401,7521,7071,7362,1256851,7311,5801,1253,3831,4743,0672,4194866051,1411,8962,7879511,6271,576946769000522
       Other Current Liabilities 
317
0
0
0
393
662
5
26
20
43
324
101
1,013
607
109
75
25
124
262
235
245
577
1,140
593
9,012
370
450
1,412
2,636
2,491
565
543
1,325
919
2,742
2,326
2,017
17,633
1,951
16,539
16,767
17,344
1,998
1,663
2,074
9,051
-743
14,886
14,886-7439,0512,0741,6631,99817,34416,76716,5391,95117,6332,0172,3262,7429191,3255435652,4912,6361,4124503709,0125931,14057724523526212425751096071,0131013244320265662393000317
   > Long-term Liabilities 
0
0
0
0
141
91
7,760
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,794
9,692
9,087
8,582
8,086
7,605
7,203
1,841
1,764
289
1,609
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
26,808
126,475
119,255
102,222
101,205
100,213
95,404
94,608
71,348
65,756
65,200
64,627
63,991
63,313
62,602
62,60263,31363,99164,62765,20065,75671,34894,60895,404100,213101,205102,222119,255126,47526,80827,34926,88827,35927,87928,36223,56521,99522,2941,6092891,7641,8417,2037,6058,0868,5829,0879,6928,7945,8125,1535,0035,2255,3836,9527,0437,760911410000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-1,597
-1,995
-3,687
-2,485
-3,331
-3,691
-4,073
-3,404
-4,141
-5,816
-6,547
-6,609
-5,076
-5,948
-6,848
-6,766
-7,356
-7,666
0
22,078
21,804
23,380
28,214
27,753
27,258
26,752
26,235
25,694
125,361
118,141
101,108
100,178
99,193
94,464
93,561
71,348
65,756
65,200
54,218
63,991
52,737
62,602
62,60252,73763,99154,21865,20065,75671,34893,56194,46499,193100,178101,108118,141125,36125,69426,23526,75227,25827,75328,21423,38021,80422,0780-7,666-7,356-6,766-6,848-5,948-5,076-6,609-6,547-5,816-4,141-3,404-4,073-3,691-3,331-2,485-3,687-1,995-1,597000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
373
455
386
370
369
387
481
404
368
187
243
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
1,114
1,114
119,255
102,222
101,205
100,213
95,404
1,047
71,348
65,756
0
0
0
0
0
0000065,75671,3481,04795,404100,213101,205102,222119,2551,1141,11427,34926,88827,35927,87928,36223,56521,99522,29424318736840448138736937038645537300000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
147
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,421
9,237
8,701
8,212
7,717
7,218
6,722
1,437
1,396
102
1,366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,3661021,3961,4376,7227,2187,7178,2128,7019,2378,4215,8125,1535,0035,2255,3836,9527,043147000000
> Total Stockholder Equity
0
0
0
0
-218
49,914
43,038
155,735
149,483
279,680
270,626
262,330
252,592
241,566
247,654
236,230
215,600
201,381
192,180
180,992
184,028
246,043
233,447
215,553
201,167
188,143
177,740
164,214
174,957
303,953
282,563
464,712
434,347
414,820
379,142
346,000
316,185
282,952
244,122
208,337
181,518
157,757
131,155
102,714
83,469
182,288
168,029
144,116
144,116168,029182,28883,469102,714131,155157,757181,518208,337244,122282,952316,185346,000379,142414,820434,347464,712282,563303,953174,957164,214177,740188,143201,167215,553233,447246,043184,028180,992192,180201,381215,600236,230247,654241,566252,592262,330270,626279,680149,483155,73543,03849,914-2180000
   Common Stock
0
0
0
0
0
1
-1,564
2
2
3
3
3
3
3
4
4
4
4
5
5
5
7
6
6
6
6
6
7
7
8
8
10
10
10
10
10
10
10
10
10
10
10
10
10
10
2
2
2
2221010101010101010101010101010887766666755544443333322-1,564100000
   Retained Earnings Total Equity00000-863,178-831,6680-769,876-729,745-685,984-648,076-613,667-575,305-530,972-502,536-464,904-437,135-407,935-385,029-366,104-349,986-335,032-320,543-304,884-283,926-265,116-254,062-239,273-225,444-214,014-197,915-175,521-161,220-99,560-84,168-70,074-55,991-46,224-36,715-26,324-18,069000000
   Accumulated Other Comprehensive Income 
0
0
0
0
27
27
26
11
10
-33
12
-3
-11
9
4
-19
-7
-212
-403
-551
-963
-1,021
-908
-854
-799
-754
-738
-745
-725
-833
-598
-605
-261
-316
-417
-523
-714
-1,423
-1,796
-1,953
-1,531
-799
-606
-552
-473
-533
-525
-268
-268-525-533-473-552-606-799-1,531-1,953-1,796-1,423-714-523-417-316-261-605-598-833-725-745-738-754-799-854-908-1,021-963-551-403-212-7-1949-11-312-3310112627270000
   Capital Surplus 
0
0
0
0
0
0
1,538
182,046
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
0
990,214
994,929
0
0
0
0
0
00000994,929990,2140980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,186182,0461,538000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
632
63,082
1,538
14,807
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
985,651
990,214
994,929
999,319
1,003,709
1,127,383
1,131,592
1,134,556
1,134,5561,131,5921,127,3831,003,709999,319994,929990,214985,651980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,18614,8071,53863,0826320000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.